In the face of the rapid increase in cases of monkeypox (or “monkeypox”) in France, the High Authority for Health (HAS) is recommending that contact cases be vaccinated. However, some testimonies indicate side effects that are still unknown, potentially related to vaccination.
Almost 1,500 people have already been infected. While the vaccination campaign against “monkeypox” In light of the increase in the number of cases in France, testimonies about the side effects of the vaccine are also beginning to emerge. However, health authorities continue Highly recommend Vaccination.
To better target these side effects, the National Agency for the Safety of Medicines and Health Products (ANSM) is studying and validating clinical trials of two of the 3 vaccines.The tenth The generation with Marketing Authorization (AMM), IMVANEX and JYNNEOS, manufactured by the Bavarian company Nordic, located in Denmark.
‘Classic’ side effects
According to results observed during clinical trials of the IMVANEX vaccine, “7% of people with atopic dermatitis (eczema) experienced a flare-up or worsening of their condition,” according to ANSM. in a report.
In “healthy” subjects, 40.8% showed swelling and 49.3% erythema, which are “classic” reactions after vaccination. The ANSM note also specifies that IMVANEX can cause a “localized or more widespread rash” in fairly rare cases.
From a heart perspective, ‘special reported interest’ events are relatively low. “6 cases (0.08%) were considered to be associated with JYNNEOS vaccination. Although tachycardia or palpitations may be observed in these six cases, the number remains very low. Especially” as none of these cardiac events considered relevant A causal link to vaccination is serious,” concludes ANSM.
As of July 19, 2022, 1,453 confirmed cases Monkeypox has been identified in France, according to French public health reports.
Yesterday, Thursday, July 21, the Director-General of the World Health Organization said he was “concerned” about the rise in the number of monkeypox cases as he opened an emergency committee meeting, and sought advice from experts before deciding whether to join the highest level of preparedness. the organization.
“I need your guidance in assessing the immediate and long-term public health implications of this evolving event,” said Dr. Tedros Adhanom Ghebreyesus.
